Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?

Liver International

Volumn 35, Issue 7, 2015, Pages 1862-1871

  Edenvik, Pia ^a   Davidsdottir, Loa ^a   Oksanen, Antti ^a   Isaksson, Bengt ^a   Hultcrantz, Rolf ^a   Stål, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hepatocellular carcinoma; Non alcoholic fatty liver disease; Real life management; Surveillance

Indexed keywords

SORAFENIB;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL PRACTICE; EUROPEAN; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; HEALTH SURVEY; KAPLAN MEIER METHOD; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME; UNIVERSITY HOSPITAL;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; TUMOR BURDEN;

EID: 84931570326     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12764     Document Type: Article

References (31)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
2. Cancer incidence in Sweden 2012. Available at: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19291/2013-12-17.pdf. (Accessed 17 December 2013)
3. De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatology 2012; 56(Suppl): S75-87.
4. Salgia R, Singal AG. Hepatocellular carcinoma and other liver lesions. Med Clin North Am 2014; 98: 103-18.
5. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 1: e1001624.
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
8. EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatology 2012; 56: 908-43.
9. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the japan society of hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-64.
10. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013; 11: 472-7.
11. Hassett M, Yopp AC, Singal AG. Surveillance for hepatocellular carcinoma: how can we do better? Am J Med Sci 2013; 346: 308-13.
12. El-Serag HB, Alsarraj A, Richardson P, et al. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci 2013; 58: 3117-26.
13. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res 2012; 5: 1124-30.
14. Singal AG, Yopp A, Skinner CS, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012; 27: 861-7.
15. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-9.
16. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-41.
17. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment PharmacolTher 2009; 30: 37-47.
18. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007; 5: 508-12.
19. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007; 41: 777-82.
20. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
21. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-50.
22. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40.
23. Dalton-Fitzgerald E, Tiro J, Kandunoori P, et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; Jul 11. pii: S1542-356500987-2.
24. Johnson P, Berhane S, Satomura S, et al. An international collaborative study assessing the role of aetiology and stage in survival in HCC - implications for screening. J Hepatology 2014; 60(Suppl): S45-6.
25. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012; 156: 841-7.
26. Mayorga C, Yopp AC, Singal AG. Hepatocellular carcinoma surveillance: all cirrhotic patients may not be equal. Gastroenterology 2012; 143: 1393-5.
27. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.
28. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013; 162: 496-500.
29. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-71.
30. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: an update. World J Gastrointest Oncol 2013; 5: 186-94.
31. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.